• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POSASR filed by Atai Beckley N.V

    12/30/25 8:49:58 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATAI alert in real time by email
    POSASR 1 ef20061810_posasr.htm POSASR
    As filed with the Securities and Exchange Commission on December 30, 2025

    Registration No. 333-290592



    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-290592

    under
    THE SECURITIES ACT OF 1933

    Atai Beckley N.V.
    (Exact name of registrant as specified in its charter)

    The Netherlands
    (State or other jurisdiction of incorporation or organization)

    Not Applicable
    (I.R.S. Employer Identification Number)

    Prof. J.H. Bavincklaan 7
    1183 AT Amstelveen
    The Netherlands
    +31 20 793 2536
    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    c/o atai Life Sciences US, Inc.
    c/o Industrious NYC
    250 West 34th Street
    New York, New York 10119
    (332) 282-0507
    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Approximate date of commencement of proposed sale to the public: Not applicable.

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☐

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☒

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer
    ☐
    Accelerated filer
    ☐
    Non-accelerated filer
    ☒
    Smaller reporting company
    ☒
       
    Emerging growth company
    ☒
           
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act.
    ☐



    EXPLANATORY NOTE

    On December 30, 2025, Atai Beckley N.V. (f/k/a atai Life Sciences N.V.), a Dutch public company (“atai Netherlands”) merged with and into atai Life Sciences Luxembourg S.A., a Luxembourg public limited liability company (société anonyme) (“atai LuxCo”). On December 30, 2025, atai LuxCo then consummated the conversion of atai LuxCo into a corporation incorporated under the laws of the State of Delaware, after which, atai LuxCo will continue as an entity under the name “AtaiBeckley Inc.” (the “Company” or the “Registrant”) (such transactions, the “Redomiciliation Transaction”).

    DEREGISTRATION OF UNSOLD SECURITIES
     
    This Post-Effective Amendment, filed by AtaiBeckley Inc., relates to the following Registration Statement on Form S-3 (the “Registration Statement”), previously filed with the Securities and Exchange Commission (the “SEC”) by the Registrant:


    •
    Registration No. 333-290592, filed with the SEC on September 29, 2025, providing for the offer and sale, from time to time, in one or more offerings and series, together or separately, of: (i) common shares, (ii) debt securities, (iii) warrants and (iv) units of atai Netherlands.

    As a result of the Redomiciliation Transaction, the Registrant has terminated all offerings of its securities pursuant to existing registration statements, including the Registration Statement. In accordance with an undertaking made by the Registrant in the Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities registered under the Registration Statement that remain unsold at the termination of the offering, the Registrant hereby removes from registration all of the securities registered under the Registration Statement that remain unsold as of the date hereof.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3, and has duly caused this Post-Effective Amendment to be signed on its behalf by the undersigned, thereunto duly authorized, in Encinitas, California, on the 30th day of December, 2025.

     
    ATAIBECKLEY INC. (as successor to Atai Beckley N.V.)
     
           
     
    By
    /s/ Srinivas Rao
     
       
    Srinivas Rao
     
       
    Chief Executive Officer
     

    Note: No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933.



    Get the next $ATAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATAI

    DatePrice TargetRatingAnalyst
    10/13/2025$12.00Buy
    Needham
    7/29/2025$14.00Outperform
    Oppenheimer
    4/4/2025Buy
    Berenberg
    11/18/2024$15.00 → $10.00Buy
    H.C. Wainwright
    4/3/2024$6.00Hold → Buy
    Maxim Group
    11/1/2022$18.00Buy
    Loop Capital
    11/30/2021$25.00Buy
    Maxim Group
    11/22/2021$40.00 → $50.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ATAI
    SEC Filings

    View All

    SEC Form 15-12G filed by Atai Beckley N.V

    15-12G - Atai Beckley N.V. (0001840904) (Filer)

    12/30/25 9:01:02 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form POSASR filed by Atai Beckley N.V

    POSASR - Atai Beckley N.V. (0001840904) (Filer)

    12/30/25 8:49:58 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atai Beckley N.V filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Atai Beckley N.V. (0001840904) (Filer)

    12/5/25 4:56:59 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AtaiBeckley Completes Redomiciliation to the United States

    NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced the completion of the redomiciliation of the parent company of the AtaiBeckley group from a Netherlands company to a U.S. entity incorporated in Delaware. The redomiciliation was approved by approximately 99% of the votes cast at the Company's extraordinary general meeting of shareholders on November 4, 2025. The redomiciliation was completed following the close of trading on the Nasdaq Global Market on Dece

    12/30/25 7:13:02 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)

    NEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced its common stock has been added to the NASDAQ Biotechnology Index (NASDAQ:NBI), effective prior to market open on Monday, December 22, 2025. "2025 has been a defining year for AtaiBeckley, marked by meaningful progress across our pipeline and corporate foundation. We strengthened our balance sheet by raising approximately $300 million, advanced multiple clinical programs toward late-stage deve

    12/23/25 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio

    NEW YORK and AMSTERDAM, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ:ATAI) ("AtaiBeckley" or the "Company"), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced that the United States Patent and Trademark Office has granted a new patent covering EMP-01 (oral R-MDMA), further strengthening the company's intellectual property estate and long-term exclusivity for the program. The newly granted U.S. patent, No. 12,492,178, includes claims to the drug substance of EMP-01, and is expected to provide exclusivity through 2043. This patent identifies a hig

    12/11/25 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Feilding-Mellen Cosmo

    4 - Atai Beckley N.V. (0001840904) (Issuer)

    11/26/25 5:00:26 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hershberg Robert

    4 - Atai Beckley N.V. (0001840904) (Issuer)

    11/6/25 8:54:40 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Feilding-Mellen Cosmo was granted 7,702,990 shares (SEC Form 4)

    4 - Atai Beckley N.V. (0001840904) (Issuer)

    11/6/25 8:49:06 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Apeiron Investment Group Ltd. bought $19,000,000 worth of shares (8,675,799 units at $2.19) (SEC Form 4)

    4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

    8/18/25 6:00:05 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Apeiron Investment Group Ltd. bought $2,520,000 worth of shares (1,800,000 units at $1.40) (SEC Form 4)

    4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

    3/24/25 5:00:18 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Apeiron Investment Group Ltd. bought $22,755,008 worth of shares (10,835,718 units at $2.10) (SEC Form 4)

    4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

    2/19/25 6:00:05 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on atai Life Sciences N.V. with a new price target

    Needham initiated coverage of atai Life Sciences N.V. with a rating of Buy and set a new price target of $12.00

    10/13/25 8:51:27 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on atai Life Sciences N.V. with a new price target

    Oppenheimer initiated coverage of atai Life Sciences N.V. with a rating of Outperform and set a new price target of $14.00

    7/29/25 7:39:06 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Berenberg initiated coverage on atai Life Sciences N.V.

    Berenberg initiated coverage of atai Life Sciences N.V. with a rating of Buy

    4/4/25 8:27:07 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Leadership Updates

    Live Leadership Updates

    View All

    atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

    - Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer- Kevin Craig, M.D. promoted to Chief Medical Officer- Glenn Short, Ph.D. promoted to Chief Scientific Officer- Gerd Kochendoerfer, Ph.D. joins as Chief Operating Officer NEW YORK and BERLIN, Jan. 10, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced key leadership appointments to advance its goal of delivering novel mental health therapeutics. Srinivas Rao M.D., Ph.D., has assumed the role of sole Chief Executive Officer (CEO), joined by the promotions of Kevin Craig, M.D.

    1/10/25 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors

    NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai's supervisory board ("Board") subject to applicable legal requirements. Scott Braunstein, M.D., is the Chief Executive Officer ("CEO") and Chairman of Marinus Pharmaceuticals, Inc. He is an operating partner at Aisling Capital and serves on the Board of Directors at both Caribou Biosciences, Inc. and Trevena Inc. Previously, Dr. Braunstein was Chief Operati

    5/23/24 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    atai Life Sciences Appoints Anne Johnson as Chief Financial Officer

    NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company") today announced that Anne Johnson, the Company's interim Chief Financial Officer since October 2023 and Chief Accounting Officer since August 2022, has been named Chief Financial Officer (CFO). Anne succeeds Stephen Bardin as the Company's CFO while Stephen will continue in an advisory role until March 31, 2024 to support the transition. "Anne has been an integral member of our team for over three years and has demonstrated the executive leadership, financial acumen, and track record to lead our financial organization with excellence," said atai Co-founder and Chief Executive Off

    2/6/24 5:00:31 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Financials

    Live finance-specific insights

    View All

    AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression

    A 12 mg dose of BPL-003 (mebufotenin benzoate nasal spray) administered eight weeks after an initial 12 mg, 8 mg or 0.3 mg dose in the core study of the Phase 2b clinical trial produced additional rapid, clinically meaningful antidepressant effects that were sustained for up to eight weeksPatients who received an active dose of BPL-003 in the core study of the Phase 2b clinical trial (either 8 mg or 12 mg) met response and remission criteria for depression at increased rates after receiving a 12 mg dose in the OLE study, with 63% in response and 48% in remission at Week 8 in the OLE study (Week 16 of the Phase 2b clinical trial)An End-of-Phase 2 meeting has been scheduled with the U.S. Food

    11/10/25 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

    Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single doseBoth 8 mg and 12 mg single doses of BPL-003 showed statistically significant and clinically meaningful reductions in depressive symptoms at all time points of the study compared to a 0.3 mg low-dose active control out to Week 8BPL-003 was generally well-tolerated at all doses, with 99% of treatment-emergent adverse events being mild or moderate, and no drug-related serious adverse events or suicide-related safety signalsMajority of patients deemed ready for discharge at the 90 minutes post-dose assessment, which suggests BPL-003 could fit within t

    7/1/25 6:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

    Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinicCombined company will operate under the name atai Beckley with a joint leadership team and Board that leverage the deep psychedelic, drug development and CNS expertise within both organizationsTopline data from the Phase 2b study of BPL-003 in patients with treatment-resistant depression (TRD) is expected in mid-2025 - the largest controlled trial of mebufotenin (5-MeO-DMT) and the first and only controlled trial to investigate mebufotenin in the U.S

    6/2/25 6:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ATAI Life Sciences N.V.

    SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)

    9/27/24 7:56:26 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by ATAI Life Sciences N.V. (Amendment)

    SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)

    5/3/24 4:06:02 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by ATAI Life Sciences N.V. (Amendment)

    SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)

    3/12/24 9:30:31 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care